Skip to main content
Premium Trial:

Request an Annual Quote

NCRR Has $43M for Shared Instruments in '11

NEW YORK (GenomeWeb News) – The National Institutes of Health will grant roughly $43 million in fiscal year 2011 for its Shared Instrument Grant program, which provides funds to institutions seeking to buy expensive biomedical research equipment.

The program, administered by the National Center for Research Resources, will support the purchase of instruments and tools costing at least $100,000 and as much as $600,000, including tools such as DNA sequencers, mass spectrometers, cell sorters, biosensors, confocal and electron microscopes, X-ray diffraction systems, and NMR spectrometers.

The program gives funding to universities, non-profit organizations, private institutions, colleges, or hospitals.

The SIG's objective is to help these institutes acquire expensive research instruments that can only be justified on a shared-use basis and which will be used in meritorious NIH-funded, basic, translational, or clinical research.

It will fund the purchase of or upgrade to a single expensive, specialized, commercially available instrument or an integrated instrument system, such as one in which the components, when used in conjunction with one another, perform a function that no single component could provide.

Although the central aim of the SIG program is to buy tools such as DNA sequencers, mass spectrometers, and other biological and biomedical research tools, some information technologies such as computer systems, supercomputers, clusters, and storage systems may be applicable for funding if the tools are solely dedicated to the research needs of a broad community of NIH-supported investigators.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.